

Brought to you by Why Summits for our PPM Workout Platform, where we hold each other accountable.
www.ppmworkout.com



16th Biopharma & MedTech PPM Conference - East Coast

- The most popular PPM conference for Pharmaceutical managers worldwide.
- •June 7-8, 2022 | Philadelphia, PA (in-person event)
- Venue: Hilton Philadelphia City Avenue

Gold Sponsors









Silver Sponsors





Bronze Sponsors





PPM Summits Worldwide





The event's moderators





in

Darshan Shah
Pharmaceutical Executive, Experienced Team Leader
Incyte

Mark Christopulos
Senior Director, Portfolio Management



CSL Behring

Mark Kleinman

Senior Project Director

CSL Behring



Nara Gubbala
Principal PPM consultant
Gubbala Inc.





Matthew Kokkonen
Senior Director of R&D Operations
Clover BioPharma



Speakers and Panelists



Medtronic



MIRAT



S CLOVER







Sangame Sangame

Michael O'Connor Senior Research Program Director, Program Management Medtronic

Joe Stalder Senior Director, Project Manager Mirati Therapeutics

Matthew Kokkonen Senior Director of R&D Operations Clover BioPharma

Monika Sharma **VP Product Development** Wugen

Elke Vogt Principal Project Manager Sangamo Therapeutics

Anne Wong Senior Project Manager Sangamo Therapeutics



CSL Behring



EQ_R



REGENERON



AstraZeneca 2



MERCK



Encoded >

Mark Kleinman Senior Project Director CSL Behring

Corky LaVallee Global Program Team Director **EORx**

Kris Sprague Head, Project Planning and Scheduling Regeneron

Eric Towler Senior Director, GPPM Late Oncology AstraZeneca

Sachin Raje Director, Strategy Realization Office, MRL Global Medical and Scientific Affairs Merck

Stephen Smith Lead program strategy development and execution **Encoded Therapeutics**







Darshan Shah Pharmaceutical Executive, Experienced Team Leader Incyte

M



Mark Christopulos Senior Director Portfolio Management







Ivan Kugener Andrew Combs VP, Head of Global Portfolio Senior Analyst Management, Valuation & Analytics Captario Merck KGaA



abbvie

Jenifer Christensen VP Strategic Initiatives AbbVie



Nara Gubbala Principal PPM consultant Gubbala Inc.





David Townson Executive, Oncology Research and Development Bayer





Cynthia Shafer Chief of Staff, Clinical Development Arcus Biosciences



#CGONCOLOGY

Robbi Sera VP, Enterprise Project and Alliance Manager CG Oncology, Inc.



Richard Bayney President & Founder, Portfolio Manager & Decision Analysist PPVC









O CHEMENCE

Wendy Takken PMO Director, Chemence







Vincent Turula
Senior Director
LEXEO Therapeutics





Sathiya Prabaharan Senior Director Integra Life Sciences





Avi Garg

Decision Scientist

Captario





Amisha Boucher
Associate Director
Enrich Consulting





Lee Lambert
Founder of the PMP
Lambert Consulting Group



Planisware

Jean-Pascal Casagrande
Director of Solutions Engineering
Planisware



I Sciforma

Bobby Deal Sales Director Sciforma



ONE2TEAM

Charles Mahé
Head of Presales
One2Team a Sciforma company

9.00 **KEYNOTE:** PM vs. PL: THE ROLE OF THE PROJECT MANAGER IN FIVE CLICHÉS

It is fairly common for development programs to be executed by a cross-functional team, led by a Project Leader and supported by a Project Manager, but at times the difference between those roles can be confusing. This presentation will attempt to:

- · Provoke us to think about who we are to our teams;
- · Examine our assumptions about the PM role; and
- · Stimulate some discussion

Hopefully you will leave with a fresh perspective on what it means to be a Project Manager!

Corky La Vallee, Global Program Team Director, EQRx

9.30 **KEYNOTE:** PIVOTING YOUR PORTFOLIO OF PROJECTS FOR AGILITY IN THE FACE OF DISRUPTION

- Reacting to change quickly and effectively in real-time to avoid unwanted roadblocks
- · Gaining full transparency towards your portfolio of projects to fuel effective decision making
- Monitoring interdependencies in product lines and across platforms to strategically manage your portfolio from top to bottom
- Accelerating product launch efficiencies to increase value to the portfolio
- Managing project strategies effectively to avoid roadblocks and increase portfolio value

Jean-Pascal Casagrande, Director of Solutions Engineering, Planisware

10.00 PANEL DISCUSSION: EVOLUTION OF PMO and PORTFOLIO FUNCTION

- We will also listen to best advice from experienced PPM managers on how to build a sustainable Portfolio Management function in the organization.
- What are the responsibilities and authorities of centralized PMO function?
- · What are the common challenges and how to tackle them?
- We will evaluate which tools and methodologies are best for different types of maturity of PMO organizations.

Michael O'Connor, Senior Research Program Director, Program Management, Medtronic Matthew Kokkonen, Senior Director of R&D Operations, Clover BioPharma Kris Sprague, Head, Project Planning and Scheduling, Regeneron Sathiya Prabaharan, Senior Director, Integra Life Sciences Nara Gubbala, Principal PPM consultant, Gubbala Inc.

10.30 NETWORKING BREAK

11.00 **KEYNOTE:** HOW A PROJECT MANAGER BECOMING A PROJECT LEADER MIRRORS DRUG DEVELOPMENT ITSELF

This wonderful and insightful keynote will also include:

- An introductory example of what a leader is (not)
- · PM-Speak: our common drug development vernacular
- Using PM-speak to describe leadership development

Eric Towler, Senior Director, GPPM Late Oncology, AstraZeneca

11.30 **KEYNOTE:** DISEASE AREA STRATEGY DEVELOPMENT & SCENARIO PLANNING

Drug development and commercialization are challenging and risky endeavors, particularly true at the portfolio level. For an organization building out a disease area portfolio and the underlying strategy supporting this targeted portfolio, robust scenario planning is critical to success. An organization will need to answer key questions like what assets they should prioritize, what relationships exist across assets, how to prioritize internal versus external assets, and how to balance short- and long-term objectives. A successful, forward-looking disease area strategy will have thoroughly investigated these questions to understand critical portfolio trade-offs. Captario SUM® can help organizations build, test, and optimize disease area strategies.

Avi Garg, Decision Scientist, Captario

Andrew Combs, Senior Analyst, Captario

12.00 PANEL DISCUSSION: HOW TO PRIORITIZE PROJECTS WHEN EVERYONE IS CRITICAL

- Project prioritization is an important component of project portfolio management as it ensures that organization resources are directed towards the highest value project investments.
- In this session we will discuss best practices for utilizing the most effective Prioritization approach.

Eric Towler, Senior Director, GPPM Late Oncology, AstraZeneca

Stephen Smith, Lead program strategy development and execution, Encoded Therapeutics

Darshan Shah, Pharmaceutical Executive, Experienced Team Leader, Incyte

12.30 NETWORKING LUNCH

13.30 PANEL DISCUSSION: METHODOLOGIES FOR RISK AND DECISION ANALYSIS

- We will discuss how to shape the strategic and financial goals of your company by using compelling and actionable portfolio analysis to influence corporate decision-makers.
- We will discuss how to quantify and manage risk at project, program, and portfolio levels, how Quantify the likelihood that your R&D pipeline portfolio and commercial portfolio will meet annual corporate targets.

Matthew Kokkonen, Senior Director of R&D Operations, Clover BioPharma

Eric Towler, Senior Director, GPPM Late Oncology, AstraZeneca

Stephen Smith, Lead program strategy development and execution, Encoded Therapeutics

Mark Christopulos, Senior Director, Portfolio Management



14.00 **KEYNOTE:** PORTFOLIO MANAGEMENT IS A PROCESS, NOT A TOOL: LESSONS LEARNED FROM OVER 20 YEARS OF PRACTICE

Portfolio management is change management. Effective portfolio management demands a departure from the status-quo and impacts many stakeholders across the organization. Successful rollout requires careful change management at each step of the process.

- Get buy-in from all key stakeholders before moving ahead
- Phase things in manageable chunks instead of taking on too much at once
- Plan sufficient resources and time for each phase
- · Make data integrity a top priority
- · Add new features slowly
- Offer sufficient training and support

Amisha Boucher, Associate Director, Enrich Consulting

14.30 PANEL DISCUSSION: INNOVATION PORTFOLIO RISK MANAGEMENT

Pharmaceutical business is an innovative business, still different organizations are defining innovation differently. Implementation of innovation management structures allows the developing of an innovation culture across a company and to boost its portfolio. We can look for new innovative products like Gene therapies, Precision medicine, Digital Therapeutics.. or look for new innovative ways of working and utilizing new technologies and methodologies in our work. To align this with risk management is a task everyone faces.

- · Risk valuation as a powerful tool in project and portfolio management
- · Identifying the soft factors that drive risk evaluation
- What is risk? How Do We Perceive Risk?
- How can we manage risk in a project and in a portfolio?
- Why is risk management needed for Biopharma Projects?
- What is the traditional risk management approach?
- How can we make risk management fast and light to pace with agile projects?
- · How do risk assessment results drive portfolio decisions?

Elke Vogt, Principal Project Manager, Sangamo Therapeutics Kris Sprague, Head, Project Planning and Scheduling, Regeneron Sathiya Prabaharan, Senior Director, Integra Life Sciences Nara Gubbala, Principal PPM consultant, Gubbala Inc.

15.00 NETWORKING BREAK

.30 PANEL DISCUSSION: BEHAVIOR OF INTERNAL STAKEHOLDERS IN PROJECT PORTFOLIO MANAGEMENT AND ITS IMPACT ON SUCCESS

Stakeholder behavior and stakeholder management are key success factors within project portfolio management.

The expert panel will address:

- How does the behavior of internal stakeholders influence project portfolio success?
- How does the intensity of engagement of stakeholders influence project portfolio success?
- How does a stakeholders' influence on success vary across different PPM phases?
- How is the influence of stakeholder behavior on success affected by role clarity?

Darshan Shah, Pharmaceutical Executive, Experienced Team Leader, Incyte

Jenifer Christensen, VP Strategic Initiatives, AbbVie

Mark Christopulos, Senior Director, Portfolio Management

Mark Kleinman, Senior Project Director, CSL Behring

16.00 **KEYNOTE:** MAKING METHODOLOGY MAGIC

Mirati Therapeutics shares how their partnership with Project Widgets helped automate their PPM methodology.

- A behind-the-scenes look at the PPM methodology at Mirati
- The introduction of widgets to the Mirati PMO
- · Game-changing impact of automation
- Preview of enterprise-level Microsoft Project solutions

Ira Brown, President and CEO, Project Widgets

Gabe Young, Executive Vice President, Project Widgets

Joe Stalder, Executive Director, Project Management, Mirati Therapeutics

16.30 PANEL DISCUSSION: BEHAVIOR OF EXTERNAL STAKEHOLDERS and STAKEHOLDER MANAGEMENT – MERGERS & ACQUISITIONS, STRATEGIC ALLIANCES AND JOINT VENTURES

- What does the ideal business model look like and how can we achieve it
- Building partnerships and deciding on the volume of business given
- Best practises for establishing relationships with external organisations
- · Managing difficult relationships
- "what was a mistake you made, and what did you learn from it"
- Strengthening Our Relationships, especially for someone coming on project later
- Proactively Setting Expectations
- Resetting expectations in a positive way that builds the relationship
- · When to cut ties

We will discuss the roles of different stakeholders, examples of mature and non-mature systems.

We will look at how to identify stakeholders, how to do assessment of stakeholder behaviour, and its consequences.

- · Role and involvement of line managers
- · Role and involvement of senior managers in PPM
- Role of the portfolio and project portfolio managers What is the ideal system?

Michael O'Connor, Senior Research Program Director, Program Management, Medtronic Matthew Kokkonen, Senior Director of R&D Operations, Clover BioPharma Kris Sprague, Head, Project Planning and Scheduling, Regeneron

17.00 **KEYNOTE:** CHASING THE LONG-RANGE GROWTH PLAN: A NECESSARY PREOCCUPATION OF PORTFOLIO MANAGEMENT

Synopsis

While every organization has a long-range growth plan (LRGP) that represents its annual sales growth aspirations, it is often shrouded in uncertainty and ambiguity largely because it is disconnected from the Strategic Plan (SP). This presentation examines many of the flaws encountered by organizations willing to create LGRPs that seemingly assume an independent life of their own and proposes solutions to avoid unnecessary confusion and consternation.

The following topics are addressed:

- What does the LGRP have to do with the SP?
- · On what basis is the LGRP created?
- Apply non-quantitative performance metrics.
- Pick a number!'
- Apply potential sales to a stretch target.
- Use risk-adjusted sales as a basis for discussion.
- How likely is it that the LGRP can be achieved at the portfolio level?
- What are the implications to Therapeutic Areas (TAs) to achieving the LRGP?
- To what extent does the LRGP force you to re-allocate resources especially at the TA level?
- How willing are you likely to trade-off short-term value creation for longer-term value extraction?

Richard Bayney, President & Founder, Portfolio Manager & Decision Analysist, PPVC

9.00 **KEYNOTE:** THE PROJECT MANAGER OF THE FUTURE

The idea is to talk about the kind of skills and opportunities that will present themselves for the project manager of the future to be better prepared.

As technology continues to evolve and the ways of working continue to change because of the pandemic, project management cannot afford to be static and will need to morph to handle the new challenges more effectively. What would those skills look like? What would need to change in PM attitudes, skills and capabilities?

Sachin Raje, Director, Strategy Realization Office, MRL Global Medical and Scientific Affairs, Merck

9.30 KEYNOTE: ACCELERATE PORTFOLIO DECISIONS WITH A PRODUCT PORTFOLIO MANAGEMENT SOFTWARE

How Sciforma's clients are using Sciforma/One2Team platform to:

- achieve visibility and transparency for forward-looking management
- · make more insightful and reliable strategic decisions

Bobby Deal, Sales Director, Sciforma

Charles Mahé, Head of Presales, One2Team, Sciforma

10.00 PANEL DISCUSSION: 101 OF PPM

The success of the project portfolio strategy and management process is dependent on having a strong portfolio group with access to the project data, the ability to process large amounts of the data to answer 'what if' questions to create different scenarios and access to executives who would listen to the insights from the analysis. They use different portfolio selection methods – quantitative and qualitative. Come listen to the fundamental basics of PPM. This session will discuss the roles of project and portfolio management in different organizations and their role in:

- Coordination, tract and help advance both internal project activities as well as activities of external
 collaborators and service providers to achieve program milestones/goals and corporate objectives.
- · Communication with senior management, and others, regarding program strategies, resources, timelines
- Development of operational plans, including timelines, budget and resource planning, risk assessment, and contingency planning.
- · Forecasting, tracking, and adherence to program timelines and budget. (Headcount and external costs).
- Cross-functional alignment and organizational support for the execution of the operational plan by facilitating internal and external stakeholder meetings
- Monitoring and tracking the project against approved timelines and milestones
- Implementing communication plans to promote effective dialogue among stakeholders and navigate arbitration mechanisms to resolve issue escalations.
- Building transparency and clarity of program goals progress and issues

Monika Sharma, VP Product Development, Wugen

Sachin Raje, Director, Strategy Realization Office, MRL Global Medical and Scientific Affairs, Merck Mark Christopulos, Senior Director, Portfolio Management

10.30 NETWORKING BREAK

WHY?

"ALWAYS BE CURIOUS"

11.00 **KEYNOTE:** HOW TO OPERATIONALLY PRIORITIZE EARLY AND LATE CLINICAL ASSETS; TAKING INTO CONSIDERATION TIME VALUE & COMPETITIVE PRESSURE

In this session, Ivan will share with you the financial methodology, the way the company models and then graphically reports on this topic to support a categorization of the company's projects. We will then look at how the organization uses this information to inform and impact the portfolio operational execution.

Ivan Kugener, Vice President, Head of Global Portfolio Management, Valuation & Analytics
Merck KGaA

11.30 PRESENTATION: BRING PRODUCTS TO MARKET ON TIME WITH A SINGLE SOURCE OF TRUTH AND AUTOMATED REPORTING

- Getting meaningful insights into projects, programs and resources across portfolios
- Streamlining project data and delivering a more complete overview to leadership
- Moving from manual spreadsheets to an automated real-time view of the portfolio
- qHighlighting exceptions in the portfolio and providing drill-down exploration

Mark Read, Client Success Manager, Sensei Projects Solutions Wendy Takken, PMO Director, Chemence

12:00 PANEL DISCUSSION: NEW WAYS OF WORKING IN PPM (DIGITALIZATION, AI, PPM TOOLS UTILIZATION)

PPM/PMO Leaders must enable collaboration between humans and smart machines for agile portfolio management. In this session, you will hear how to scale your PPM processes, tools, and functions to position your organization for success in the digital era, as well as the use of how AI can be applied to PPM from a broader portfolio perspective as well as individual projects.

Digital business requires agility and speed, continuous change, and the embracing of uncertainty. The digital environment is constantly morphing, requiring leaders to adapt. To progress toward digital success, PPM leaders must re-evaluate and re-invent their disciplines, metrics, and tools – failure to adapt will be fatal.

Joe Stalder, Senior Director, Project Manager, Mirati Therapeutics
Cynthia Shafer, Chief of Staff, Clinical Development, Arcus Biosciences
Nara Gubbala, Principal PPM consultant, Gubbala Inc.
Lee Lambert, Founder of the PMP, Lambert Consulting Group

12.30 NETWORKING LUNCH

KEYNOTE: THE MIX OF REMOTE WORKING AND LOW/NO-CODE AUTOMATION OF PPM PROCESS AND ITS ACCELERATION IN THE NEW EVOLUTION OF OUR PROFESSION For decades now, the fear of automation and robots has struck fear in the heart of workers. A key limiter has been the complexity to code processes, integration across different software applications, and the absence of tools that allow for the easy implementation of these processes. Times are changing quickly and the effects will be significant. What were some of the harbingers of this next phase of portfolio/program/project management? What are some specific areas of our work that will be next? How will we be able to remain competitive and relevant? How does the remote work revolution impact all the above?

Matthew Kokkonen, Senior Director of R&D Operations, Clover BioPharma

13.30

14.00 PRESENTATION: PROJECT MANAGEMENT VERSUS PROGRAM MANAGEMENT IN BIOTECH -THEORY VERSUS REALITY

Overview: While the definitions of project and program management are easily understandable, in practice it can be difficult to delineate the point where project management stops and program management begins. In this keynote, the following will be discussed:

- The role for project managers in large and small organizations and how that role evolves as an organization matures
- When program management becomes a crucial asset for an organization
- · How program managers must adapt depending on the capabilities of other parts of an organization

Cynthia Shafer, Chief of Staff, Clinical Development at Arcus Biosciences

14.30 PANEL DISCUSSION: ROLE OF PMs IN A MATURE PPM ORGANIZATION VS A START-UP ENVIRONMENT

Maturity of the PMO in your organization might be different.

Project Managers working on their individual projects face new requirements when the PMO function is evolving. Listen to this panel discussion to benchmark the role of Project Managers in both, early stages of PMO and mature PMO function. Governance, influence, reporting, data management topics will be discussed.

Robbi Sera, VP, Enterprise Project and Alliance Manager, CG Oncology, Inc.

Elke Vogt, Principal Project Manager, Sangamo Therapeutics

Vincent Turula, Senior Director, LEXEO Therapeutics
Mark Kleinman, Senior Project Director, CSL Behring

Corky LaVallee, Global Program Team Director, EQRx

15.00 NETWORKING BREAK

15.30 PANEL DISCUSSION: ONCOLOGY PROJECTS - WINNING ELEMENTS

Listen to inspiring project management best practice to bring needed medicines to oncology patients.

Monika Sharma, VP Product Development, Wugen

Anne Wong, Senior Project Manager, Sangamo Therapeutics

Corky LaVallee, Global Program Team Director, EQRx

David Townson, Executive, Oncology Research and Development, Bayer

Darshan Shah, Pharmaceutical Executive, Experienced Team Leader, Incyte

16.00 PANEL DISCUSSION: CHANGE MANAGEMENT

We know that for strategy to succeed, it must be supported by an organization's culture, but creating this alignment can be especially difficult in the context of a rapidly changing pharmaceutical industry. We will discuss

 How does change management fit into project management and the various topics being discussed at this summit?

- · Discuss how change needs to be addressed differently at different sized organizations you have worked at or with
- Why is change management so important now given the current circumstances?
- Why do change management fail?
- Essential role of sponsorship
- Leveraging the business case for change to generate desire for change
- Typical potholes that impede progress of change
- · What happens if your change management is inadequate?

Mark Christopulos, Senior Director, Portfolio Management

Joe Stalder, Senior Director, Project Manager, Mirati Therapeutics

Richard Bayney, President & Founder, Portfolio Manager & Decision Analysist, PPVC

Matthew Kokkonen, Senior Director of R&D Operations, Clover BioPharma

16.30 PANEL DISCUSSION: GENE AND CELL THERAPY

Cell and Gene Therapies provide innovative therapeutic treatments for complex conditions. This next generation of medicine has the potential to tackle illnesses that were once untreatable. However, getting a cell and gene therapy developed, manufactured, and approved on the market is tough. It is critical for individuals and teams to continually update and advance their knowledge and skills in this rapidly evolving area. In this session, we will listen to professionals on their experiences within this very hot sector of the pharma industry.

Anne Wong, Senior Project Manager, Sangamo Therapeutics

Mark Kleinman, Senior Project Director, CSL Behring

David Townson, Executive, Oncology Research and Development, Bayer

PANEL DISCUSSION: RESOURCE MANAGEMENT

Strategic resource management is critical in meeting business objectives, selecting and retaining the best talent and achieving financial effectiveness of an organization. With ambitious R&D agendas to be delivered under flat budgets, maintaining competitive edge in a resource constraint environment can be very challenging. We will share some approaches of resource modeling and forecasting, capacity planning, and methods to align productivity to short-term and long-term organizational strategy. We will also share some approaches to attract, develop, engage, retain and motivate scarce and highly specialized resource capabilities.

- 1. What is RM (distinguishing capacity planning vs. demand management)?
- 2. Is RM "all or none"?
- 3. Considerations for RM in life science
- 4. Best practices for RM in life sciences
- 5. When is RM needed in your company?

Joe Stalder, Senior Director, Project Manager, Mirati Therapeutics

Mark Christopulos, Senior Director, Portfolio Management

Lee Lambert, Founder of the PMP, Lambert Consulting Group



17.00

PPM Workout Platform - an online space which holds you accountable -

PPM Workout Platform

- an online space which holds you accountable

What's in it for you?

What is PPM Workout Platform?

Our idea with this in mind is to create a space for sharing and learning the best practices in PPM together, so that we can discuss and contribute to the solutions with experts in the field and build supportive relationships with like-minded professionals in order to bring the drugs to market more efficiently and in a shorter time.

The idea of a community platform is perfect, yet it won't work without you. The magic of community can be evident only when its members are open to peer-to-peer support and hence everybody gets instant access to knowledge base. Without your contribution, it's only a platform without life.

Let's maximize the benefits of the virtual world, getting to know people, on a larger scale and around the world, who we otherwise wouldn't meet.

Plenty of goodies are in the bag!

Why Summits creates opportunities for growing your professional impact. That's why it's our role to create a platform and to listen to your desires. Do you have an idea for a webinar? Do you want to host one? Do you want your challenge to be solved by other experts? Do you want to stand out from the crowd with an excellent idea you might have? Then this platform is for you!

No idea is out of limits, we, at PPM Workout platform, are highly welcoming to any ideas or suggestions for improvements, content, or events. Help us co-create an inspirational place and consequently help others to grow professionally along the way. It is a great space to be a part of and to build together.

At the heart of each community are its members. Become one for our PPM Summer Talks conference on

www.ppmworkout.com and then stay there to keep on being constantly inspired.

Join the PPM community of professionals here:

www.ppmworkout.com

ALWAYS BE CURIOUS"

12

www.whysummits.com/ppm

Our 2020/21 partners





2022 PPM Summits World at a glance

June 7 - 8, PHILADELPHIA, PENNSYLVANIA
 16th American Pharma & MedTech PPM Conference – East Coast
 October 18 - 19, Basel, Switzerland
 Innovations in CAPEX project delivery in Pharma and Biotech

November 1 - 2, San Francisco, California

Project Program and Portfolio Risk Analysis Master Class with Richard Bayney, the President & Founder of Project & Portfolio Value Creation

November 3 - 4, San Francisco, California

17th American Pharma & MedTech PPM Conference – West Coast

November 8 - 9, London, UK

21st European Pharma & MedTech PPM Conference – Autumn Edition

November 10 - 11, London, UK

Decision Analysis & Portfolio Management Master Class with Richard Bayney, the President & Founder of Project & Portfolio Value Creation



Sponsorship

Exhibiting

With a large and senior audience and decision makers, thoroughly selected, exhibiting at any Summit at 2022 PPM SUMMIT WORLD is a popular sponsorship option with great value for solution providers.

Sponsorship includes:

- Selected Summit Three Access Passes
- Exhibition space
- Helping to prearrange face to face meetings with selected participants

Dinner Sponsorship

2022 PPM SUMMIT WORLD TOUR will host a series of dinners These dinners bring together thoughtfully selected groups of 15-20 peers from established pharma, biotech, healthcare, and medtech companies. The dines start with a 30 minute networking reception followed by a 60 minute seated dinner, with the option for participants to remain afterward to continue networking.

- Selected Summit Three Access Passes
- 30-minute reception, and 60 minute seated dinner

Speaking

"ALWAYS BE CURIOUS"

Limited speaking opportunities are available for our sponsoring partners to demonstrate the expertise of their organization. Be sure to ask about these early so we can ensure your presentation flows seamlessly with the overall content. Speaking sponsorships has several options – keynote presentations, case study presentations, expert presentations, panel discussions, workshops or roundtable leadership. Speaking opportunities are available for experts in the field of Project and Portfolio Management, Contract Management, Consultancy, CMO, CRO, Data Management and Intelligence, Artificial Intelligence, Robotics, IoT and Digital Innovations

Additional sponsorship opportunities are available for those who wish to further customize their involvement.

Why did we create PPM Summit World Tour for the Health Industry?

"the most important thing to me, and millions of others, is our health."

Since growing up and moving houses a lot, I have always been surrounded by different communities, people from different backgrounds, from different cultures. From a very early age, I was always able to really talk to people, to understand them and to bring them together and to themselves.

I grew up as an only child, brought up by a single mother in the tiniest apartment you can imagine. We didn't have much but we had it all. Until one day, when things in life got twisted and I stopped seeing the closest people from my family, they were no longer there.

My gorgeous uncle, who was like a brother to me, got hit by a train at a very young age, and didn't make it after a few hours of resuscitation. The entire ambulance team couldn't save his life. This loss has carried its consequences when his father, my grandpa, my only father I ever had, couldn't understand the loss of his only son. He gave up and started medicating himself, heavily. A few years later, he died of a liver damage and a broken heart. I watched my family being torn apart and I found myself not understanding what was going on. I stood there, at the age of 12, unable to help, unable to understand, unable to find someone who could have helped. Health was only mentioned when someone stayed home with a flu and had to take medications for a headache. And all of a sudden, health turned to be something else than the picture drown on a box of a cough sirup. Mental health was of no subject, and there were no medications or drugs which could have saved either of the men in my life. Back there, in those heavy, painful moments, I promised myself to do what I can to be aware of possibilities for better life, for better health. To talk about health in a deeper manner, to open up about those unwanted and not so easy to hear conversations.

I am not, by any means, a studied doctor, or I cannot, by any chance, treat patients or give any advice. But, I always knew I wanted to help people, I was always drown to it. I have a gift to feel when someone is aching, I somehow feel the spot. Funny, because feelings don't really go hand in hand with data and science. (yet). So in my life, I opted for a balance to keep all of this in my life.

I embarked on a challenging and wonderful journey to study Traditional Chinese Medicine while understanding that the power of health lies within professionals who have dedicated their whole lives in healing the society through research, data, clinical trials and science. Here began my part in helping people becoming healthier. Creating a community of people who come together to share and exchange their knowledge and groundbreaking research. I can be your stone to turn to, when you are in the need of belonging somewhere in this fast paced world.

Joining Why Summits as a Community and Relationship Manager opened up doors to me to create an environment for professionals and experts who are not scared to change this world and make it healthier, stronger, more resilient.

Me being the social butterfly I am, I am here to create community of like-minded people who meet at our conference to meet, discuss and transform.

l look forward to meeting you in 2022, somewhere. Katy Frolova PPM Summit World Organizer

Contact us



SPEAKING:

Katy Frolova

katy. frolova@why summits.com



ATTENDING AND SPONSORING:

Srihari Kamban

shk@whysummits.com





FROM **2349**\$

Why Summits Tupeho 51/d, Bratislava, Slovak Republic

www.whysummits.com/ppm

